ENZALUTAMIDE is a second-generation androgen receptor antagonist. This means it blocks the action of androgens (such as testosterone) at the receptor level.
It interferes with several steps in the hormone-signaling pathway: androgen binding to the receptor, transport of the activated receptor into the nucleus, its interaction with DNA, and the transcription of genes that stimulate cancer cell growth.
Indications
Bdenza / enzalutamide is indicated for:
Metastatic castration-resistant prostate cancer (mCRPC) – when the cancer continues to grow despite declining testosterone levels. It is also used for non-metastatic castration-resistant prostate cancer.
It can be used in combination with testosterone-lowering therapy (androgen deficiency therapy, ADT) in metastatic prostate cancer that remains sensitive to androgen reduction.
Dosage
Standard dose: 160 mg once daily. This can be four 40 mg capsules or two 80 mg tablets, if the drug is available in these forms.
It can be taken with or without food, but it is important to maintain a consistent dosing schedule.
If severe side effects occur, a dose reduction or temporary discontinuation may be necessary until the condition improves.
Side effects
Like any potent drug, enzalutamide has a number of potential side effects. Here are the main ones:
Common
Fatigue, weakness, asthenia
Hot flashes
Headache, dizziness, decreased concentration, possible cognitive impairment